Drug Trial Radar · NCT01629966
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
Last checked: Nov 20, 2026Latest source record: Dec 18, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
680
Actual
Start
Jun 30, 2012
Primary completion
Feb 28, 2014
Study completion Mar 31, 2014
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Jun 28, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)
Conditions
- Generalized Anxiety Disorder
Interventions
PlaceboDrug
Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
VilazodoneDrug
Vilazodone, 20mg, oral administration once per day.
VilazodoneDrug
Vilazodone, 40mg, oral administration once per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) Total ScoreTime frame: Baseline to Week 8
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Forest Investigative Site 001
Birmingham, Alabama
Forest Investigative Site 021
Beverly Hills, California
Forest Investigative Site 023
Glendale, California
Forest Investigative Site 011
Paramount, California
Forest Investigative Site 026
Norwich, Connecticut
Forest Investigative Site 027
Waterbury, Connecticut
Forest Investigative Site 005
Delray Beach, Florida
Forest Investigative Site 014
Oakland Park, Florida
Forest Investigative Site 019
South Miami, Florida
Forest Investigative Site 038
Atlanta, Georgia
Forest Investigative Site 035
Decatur, Georgia
Forest Investigative Site 028
Chicago, Illinois
Forest Investigative Site 030
Schaumburg, Illinois
Forest Investigative Site 029
Topeka, Kansas
Forest Investigative Site 033
Wichita, Kansas
Forest Investigative Site 010
Lake Charles, Louisiana
Forest Investigative Site 031
Baltimore, Maryland
Forest Investigative Site 025
Boston, Massachusetts
Forest Investigative Site 037
St Louis, Missouri
Forest Investigative Site 015
Las Vegas, Nevada
Forest Investigative Site 016
Berlin, New Jersey
Forest Investigative Site 007
Brooklyn, New York
Forest Investigative Site 024
New York, New York
Forest Investigative Site 032
New York, New York
Forest Investigative Site 012
New York, New York
Forest Investigative Site 020
Bismarck, North Dakota
Forest Investigative Site 008
Cincinnati, Ohio
Forest Investigative Site 041
Dayton, Ohio
Forest Investigative Site 004
Oklahoma City, Oklahoma
Forest Investigative Site 034
Oklahoma City, Oklahoma
Forest Investigative Site 013
Portland, Oregon
Forest Investigative Site 006
Memphis, Tennessee
Forest Investigative Site 017
Wichita Falls, Texas
Forest Investigative Site 003
Salt Lake City, Utah
Forest Investigative Site 018
Charlottesville, Virginia
Forest Investigative Site 040
Bellevue, Washington
Forest Investigative Site 039
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.